following an abbreviated submission:
indacaterol/mometasone furoate (Atectura Breezhaler®) is accepted for use within NHSScotland.
Indication under review: as a maintenance treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short-acting beta2-agonists.
Indacaterol/mometasone furoate (Atectura Breezhaler®) offers an additional treatment choice of inhaled corticosteroid (ICS) and long-acting beta2-agonist (LABA) in a single inhaler. SMC has previously accepted alternative LABA / ICS combinations for use in asthma.
Download detailed advice729KB (PDF)
- Medicine name:
- indacaterol/mometasone furoate (Atectura Breezhaler)
- SMC ID:
As a maintenance treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists
- Pharmaceutical company
- Novartis Pharmaceuticals UK Ltd
- BNF chapter
- Respiratory system
- Submission type
- Date advice published
- 10 May 2021